Infección de la piel y partes blandas | 24 SEP 12

Diagnóstico y tratamiento de la celulitis

Es necesario modificar las recomendaciones existentes teniendo en cuenta el Staphylococcus aureus resistente y emplear nuevos sistemas de clasificación, como los criterios de Dundee.
Autor/a: Dres. Phoenix G., Das S., Joshi M BMJ 2012;345:e4955
INDICE:  1. Artículo | 2. Referencias

1. Department of Health. Hospital episode statistics. Primary diagnosis 2008-2009.NHS Information Centre,
2. NHS. Institute for innovation and improvement. Quality and service improvement tools.
3. BluntI, Bardsley M, Dixon J. Trends in emergency admissions in England 2004-9. The Nuffield Trust,
4. Australian Institute of Health and Welfare. Australian hospital statistics 2001-02.2003.
5. Agency for Healthcare Research and Quality. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Overview of the Nationwide Inpatient Sample (NIS). June
6. National Hospital Ambulatory Medical Care Survey: 2008 Emergency Department
7. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008;168:1585-91.
8. Chira S, Miller LG. Staphylococcus aureus is the most common identified cause of cellulitis: a systematic review. Epidemiol Infect 2010;138:313-7.
9. Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J R Soc Med 1998;91:634-7.
10. Clinical Resource Efficiency Support Team (2005) Guidelines on the management of cellulitis in adults. Crest, Belfast., %20CREST,%2005.pdf
11. LiuC, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011;52:e18-e55.
12. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007;51:3298-303.
13. UK Dermatology Clinical Trials Network’s PATCH Trial Team, Thomas K,Crook A, Foster K, Mason J, Chalmers J, et al. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network’s PATCH II trial. Br J Dermatol 2012;166:169-78.
14. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 2006;144:309-17.
15. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, et al. Methicillin-resistant S aureus infections among patients in the emergency department. N Engl J Med 2006;355:666-74.
16. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis 2010; 10:227-39.
17. Halpern J, Holder R, Langford NJ. Ethnicity and other risk factors for acute lower limb cellulitis: a UK-based prospective case-control study.Br J Dermatol 2008;158:1288-92.
18. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, et al. Risk factors for erysipelas of the leg (cellulitis): case-control study.BMJ 1999;318:1591-4.
19. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and cost of prophylaxis. Infection 1987;15:105-6.
20. Keeley VL. Lymphoedema and cellulitis: chicken or egg? Br J Dermatol 2008;158:1175-6.
21. KoD S, Lerner R, Klose G, Cosimi AB. Effective treatment of lymphedema of the extremities. Arch Surg 1998;133:452-8.
22. David CV, Chira S, Eells SJ, Ladrigan M, Papier A, Miller LG, et al. Diagnostic accuracy in patients admitted to hospitals with cellulitis. Dermatol On line J 2011;17:1.
23. Chan YL, Liao HC, Tsay PK, Chang SS, Chen JC, Liaw SJ. C-reactive protein as an indicator of bacterial infection of adult patients in the emergency department. Chang Gung Med J 2002; 25:437-45.
24. Perl B, Gottehrer NP, Ravesh D, Schlesinger Y, Rudensky B, Yinnon AM.Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis 1999; 29:1483-8.
25. Hook EW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146:295-7.
26. Holzapfe lL, Jacquet-Francillon T, Rahmani J, Achard P, Marcellin E, Joffre T, et al. Microbiological evaluation of infected wounds of the extremities in 214 adults.J Accid Emerg Med 1999;16:32-4.
27. Rabuka CE, Azoulay LY, Kahn SR. Predictors of a positive duplex scan in patients with a clinical presentation compatible with deep vein thrombosis or cellulitis. Can J Infect Dis 2003;14:210-4.
28. Tayal VS, Hasan N, Norton HJ, Tomaszewski CA. The effect of soft-tissue ultrasound on the management of cellulitis in the emergency department. Acad Emerg Med 2006;13:384-8.
29. Rahmouni A, Chosidow O, Mathieu D, et al. MR imaging in acute infectious cellulitis. Radiology 1994;192:493-6.
30. Kilburn SA, Featherstone P, Higgins B, Brindle R. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev 2010;6:CD004299.
31. Forcade NA, Parchman ML, Jorgensen JH, Du LC, Nyren NR, Treviño LB, et al. Prevalence, severity, and treatment of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) skin and soft tissue infections in 10 medical clinics in Texas: a South Texas Ambulatory Research Network (STARNet) Study.J Am Board Fam Med 2011;24:543-50.
32. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-1406.
33. Marwick C, Broomhall J, McCowan C, Phillips G, Gonzalez-McQuire S, Akhras K, et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother 2011; 66:387-97.
34. Eron L. J. Infections of skin and soft tissues: outcome of a classification scheme. Clin Infect Dis 2000; 31:287.
35. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother 2009;64:1316-24.



Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2021